Alpha Dna Investment Management LLC Blueprint Medicines Corp Transaction History

Alpha Dna Investment Management LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $330,413 - $421,957	3,879 New	3,879 $418,000
Q1 2022 May 13, 2022	SELL	$54.1 - $110.08 $782,231 - $1.59 Million	-14,459 Closed	0 $0
Q4 2021 Feb 11, 2022	BUY	$94.25 - $115.99 $1.36 Million - $1.68 Million	14,459 New	14,459 $1.55 Million
Q2 2021 Aug 10, 2021	SELL	$82.78 - $101.0 $4,304 - $5,252	-52 Closed	0 $0
Q1 2021 May 12, 2021	SELL	$90.71 - $108.28 $3,719 - $4,439	-41 Reduced 44.09%	52 $5,000
Q4 2020 Mar 24, 2021	BUY	$92.08 - $124.48 $4,788 - $6,472	52 Added 126.83%	93 $10,000
Q4 2020 Feb 16, 2021	BUY	$92.08 - $124.48 $3,775 - $5,103	41 New	41 $4,000

351

60.3M

2.25M

1.18M

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.4B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

Get notified when there are updates to the investment portfolio of Alpha Dna Investment Management LLC, based on Form 13F filings with the SEC.

Stay updated on Alpha Dna Investment Management LLC with notifications on news.